ArticleRSC advances2025
Metal-free access to 4-indolyl coumarin from coumarin 3-carboxylic acid and indole
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein, on water tandem Michael addition-decarboxylation of coumarin-3-carboxylic acids with indoles under catalysis of Amberlite IR120 afforded 4-indolyl 3,4-dihydrocoumarin. The process was extended to the synthesis of 4-indolyl coumarin derivatives upon oxidation using an organic oxidant. The wide substrate scope, high product yields, catalytic recyclability and large-scale preparation of intermediates are the noteworthy features of this methodology. This two-step process provides better yields of 4-indole-substituted coumarins as compared to the corresponding single-step palladium-catalyzed cross-coupling reactions. We also report herein for the first time that the indole-coumarin hybrid can be used as a thermal- and moisture-resistant invisible ink.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.